Last edition
News about "Priority Review Voucher (PRV)"
US FDA Approves ZANVASTRO as First Disease-Modifying Treatment for Alexander Disease
The US Food and Drug Administration (FDA) approves ZANVASTRO (zilganersen) as the first disease-modifying treatment for Alexander Disease (AxD) in pediatric and adult patients.
Priority Review Voucher (PRV) | 05/09/2026 | By News Bureau
Atossa Therapeutics receives US Food and Drug Administration (FDA) Rare Pediatric Disease designation for (Z)-Endoxifen in McCune-Albright syndrome, qualifying for Priority Review Voucher award upon approval.
Priority Review Voucher (PRV) | 05/05/2026 | By News Bureau | 150
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy